Terms: = Prostate cancer AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Clinical Outcome
4 results:
1. Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.
Xie W; Stopsack KH; Drouin SJ; Fu H; Pomerantz MM; Mucci LA; Lee GM; Kantoff PW
Prostate; 2019 Jan; 79(1):73-80. PubMed ID: 30141208
[TBL] [Abstract] [Full Text] [Related]
2. Expression of MMP-1, MMP-9 and timp-2 in prostate carcinoma and their influence on prognosis and survival.
Ozden F; Saygin C; Uzunaslan D; Onal B; Durak H; Aki H
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1373-82. PubMed ID: 23708302
[TBL] [Abstract] [Full Text] [Related]
3. Underexpression of MMP-2 and its regulators, timp2, MT1-MMP and IL-8, is associated with prostate cancer.
Reis ST; Antunes AA; Pontes-Junior J; Sousa-Canavez JM; Dall'Oglio MF; Piantino CB; Cruz JA; Morais DR; Srougi M; Leite KR
Int Braz J Urol; 2012; 38(2):167-74. PubMed ID: 22555040
[TBL] [Abstract] [Full Text] [Related]
4. MMP-9 overexpression due to timp-1 and RECK underexpression is associated with prognosis in prostate cancer.
Reis ST; Pontes-Junior J; Antunes AA; de Sousa-Canavez JM; Dall'Oglio MF; Passerotti CC; Abe DK; Crippa A; da Cruz JA; Timoszczuk LM; Srougi M; Leite KR
Int J Biol Markers; 2011; 26(4):255-61. PubMed ID: 22139647
[TBL] [Abstract] [Full Text] [Related]
